1-8 of 8
Robert o'Donnell
Close
Sort by
Journal Articles

Efficacy and Safety of Combined Rituximab and Ipilimumab to Treat Patients with Relapsed/Refractory CD20+ B-Cell Lymphoma

Barbara Marie Galligan, MD, Denice Tsao-Wei, Susan Groshen, Mark Kirschabum, Robert O'Donnell, Paul R. Kaesberg, MD, Tanya Siddiqui, Leslie Popplewell, Ailawadhi Sikander, Htut Myo, Robert Chen, John F. DiPersio, MD PhD, Neil D. Palmisiano, MD, David F. Claxton, MD, Edward M. Newman, PhD, Joseph Tuscano, MD
Journal: Blood
Blood (2015) 126 (23): 3977.
https://doi.org/10.1182/blood.V126.23.3977.3977
Published: 2015
Journal Articles

Clinical and Correlative Analysis of a Phase 2 Study of Lenalidomide and Rituximab in Previously Untreated Indolent Non-Hodgkin Lymphoma

Xiao-Dong Li, PhD, Ann Brunson, BS, Robert o'Donnell, Professor, Kelly M Jones, BS, Richard B Pollard, Joseph Tuscano, MD
Journal: Blood
Blood (2014) 124 (21): 4477.
https://doi.org/10.1182/blood.V124.21.4477.4477
Published: 2014
Journal Articles

Correlative Analysis and Clinical Update Of a Phase II Study Using Lenalidomide and Rituximab In Patients With Indolent Non-Hodgkin Lymphoma

Samuel Yamshon, Lihong Qi, PhD, Chaoyu Yu, Xiao-Dong Li, PhD, Robert O'Donnell, MD, PhD, Joseph Tuscano, MD
Journal: Blood
Blood (2013) 122 (21): 249.
https://doi.org/10.1182/blood.V122.21.249.249
Published: 2013
Journal Articles

The HB22.7 Anti-CD22 Monoclonal Antibody Is an Effective Platform for CD22-Targeted Antibody Drug Conjugates for Treatment of Lymphoma and Acute Lymphoblastic Leukemia

Soames F. Boyle, MD, Jason Kato, PhD, Robert O'Donnell, MD, PhD, Joseph Tuscano, MD
Journal: Blood
Blood (2012) 120 (21): 1653.
https://doi.org/10.1182/blood.V120.21.1653.1653
Published: 2012
Journal Articles

Purified, Fermented, Extract of Triticum Aestivum Has Significant Independent Lymphomacidal Activity and Augments the Activity of Rituximab

Laura Newell, Joseph Tuscano, MD, Robert o'Donnell, Professor, Yunpeng Ma
Journal: Blood
Blood (2010) 116 (21): 2857.
https://doi.org/10.1182/blood.V116.21.2857.2857
Published: 2010
Journal Articles

The Bispecific Anti-CD20/CD22 Antibody (Bs20x22) Has More Lymphomacidal Activity Than the Parent Antibodies Both Alone or In Combination

Laura Newell, Joseph Tuscano, MD, Yunpeng Ma, Shiloh Martin, Robert o'Donnell
Journal: Blood
Blood (2010) 116 (21): 425.
https://doi.org/10.1182/blood.V116.21.425.425
Published: 2010
Journal Articles

R 2 : Preliminary Results of a Phase II Study of Lenalidomide and Rituximab in Relapsed / Refractory Indolent Non-Hodgkin's Lymphoma (NHL).

Mrinal Dutia, MD, Ian DeRoock, MD, Karen Chee, MD, Robert O'donnell, MD, Christine Quirch, Christine Reed-Pease, Joseph Tuscano, MD
Journal: Blood
Blood (2009) 114 (22): 1679.
https://doi.org/10.1182/blood.V114.22.1679.1679
Published: 2009
Journal Articles

The CD22 Epitope, Dose, Dosing Interval, and Timing All Effect Efficacy of Anti-CD22 mAb-Based Therapy of NHL.

Robert O’Donnell, MD, David Pearson, PhD, Hayes McKnight, Thomas Tedder, PhD, Joseph M. Tuscano, MD
Journal: Blood
Blood (2007) 110 (11): 2355.
https://doi.org/10.1182/blood.V110.11.2355.2355
Published: 2007